Shingo Hatakeyama
Overview
Explore the profile of Shingo Hatakeyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
362
Citations
2557
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yoneyama F, Okamoto T, Hamaya T, Kodama H, Fujita N, Yamamoto H, et al.
Urol Case Rep
. 2025 Mar;
59:102978.
PMID: 40034263
Penile metastases are rare, and metastasis of a gastrointestinal stromal tumor (GIST) to the penis is exceedingly uncommon. An 81-year-old man with a history of duodenal GIST, initially treated with...
2.
Ozaki K, Yamamoto H, Sekine Y, Horiguchi H, Hosogoe S, Mikami J, et al.
Int J Urol
. 2025 Mar;
PMID: 40033773
Objective: We aimed to investigate the impact of skin adverse events (AEs) of enfortumab vedotin (EV) on prognosis in patients with locally advanced or metastatic urothelial carcinoma in real-world practice....
3.
Hara S, Fukuokaya W, Miki J, Taoka R, Saito R, Matsui Y, et al.
Int J Urol
. 2025 Feb;
PMID: 39907200
Objective: To examine the association between substaging and outcomes following radical cystectomy (RC) in patients with stage III bladder cancer. Methods: We conducted a retrospective observational study using nationwide data...
4.
Kikuchi H, Osawa T, Matsushita Y, Kojima T, Sazuka T, Hatakeyama S, et al.
Jpn J Clin Oncol
. 2025 Feb;
PMID: 39893579
Objective: To validate multiple prognostic models in metastatic renal cell carcinoma patients who received second-line axitinib following first-line nivolumab plus ipilimumab therapy. Methods: Five prognostic models (ACL, albumin, C-reactive protein,...
5.
Miura H, Yamamoto H, Okuyama Y, Ishi N, Tanaka R, Oishi T, et al.
Cancer Med
. 2024 Dec;
13(24):e70226.
PMID: 39676240
Objective: We aimed to examine trends in novel antiandrogen receptor signal inhibitor (ARSI) usage and medical costs by collecting real-world big data included in The National Database of Health Insurance...
6.
Mori K, Numakura K, Matsushita Y, Kojima T, Osawa T, Sazuka T, et al.
Cancer Sci
. 2024 Nov;
116(2):444-452.
PMID: 39550694
Nivolumab plus ipilimumab (NIVO+IPI) has a long-term response rate of 30% for patients with metastatic renal cell carcinoma (mRCC). However, 20% of patients develop primary resistant disease (PRD) to NIVO+IPI...
7.
Takehara T, Nishida H, Ichikawa K, Nawano T, Takai S, Fukuhara H, et al.
Clin Exp Nephrol
. 2024 Oct;
29(3):359-367.
PMID: 39453573
Background: Rituximab (RIT) induction therapy is widely used for desensitization against ABO-incompatible living-donor kidney transplants (KT). However, the efficacy of valganciclovir (VGCV) prophylaxis against cytomegalovirus (CMV) disease and infection in...
8.
Yanagisawa T, Fukuokaya W, Hatakeyama S, Narita S, Muramoto K, Katsumi K, et al.
Prostate
. 2024 Oct;
85(2):165-174.
PMID: 39417629
Purpose: We aimed to assess the differential efficacy and safety of androgen receptor pathway inhibitors (ARPI), such as abiraterone, enzalutamide, and apalutamide, in patients with metastatic hormone-sensitive prostate cancer (mHSPC)...
9.
Urabe F, Hatakeyama S, Yanagisawa T, Narita S, Muramoto K, Katsumi K, et al.
Urol Oncol
. 2024 Oct;
43(4):271.e9-271.e18.
PMID: 39389903
Background: Androgen receptor signaling inhibitors (ARSIs) have revolutionized the treatment of metastatic castration-sensitive prostate cancer (mCSPC). Prostate-specific antigen (PSA) dynamics, including PSA nadir, PSA response rate, and time to PSA...
10.
Kato M, Taoka R, Miki J, Saito R, Fukuokaya W, Matsui Y, et al.
Int J Clin Oncol
. 2024 Oct;
29(12):1937-1945.
PMID: 39379757
Background: Radical cystectomy in women generally includes the removal of the uterus, ovaries, and anterior vaginal wall, but the criteria for reproductive organ sparing are not clear. Methods: A total...